{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:26:28Z","timestamp":1791278788213,"version":"4.1.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1038\/nm.3253","type":"journal-article","created":{"date-parts":[[2013,7,8]],"date-time":"2013-07-08T14:28:09Z","timestamp":1373293689000},"page":"879-888","source":"Crossref","is-referenced-by-count":263,"title":["Regulation of hepatic innate immunity by hepatitis C virus"],"prefix":"10.1038","volume":"19","author":[{"given":"Stacy M","family":"Horner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Michael","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,8]]},"reference":[{"issue":"suppl. 1","key":"BFnm3253_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","volume":"29","author":"D Lavanchy","year":"2009","unstructured":"Lavanchy, D. The global burden of hepatitis C. Liver Int. 29 (suppl. 1), 74\u201381 (2009).","journal-title":"Liver Int."},{"issue":"Suppl. 1","key":"BFnm3253_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1478-3231.2008.01927.x","volume":"29","author":"LB Seeff","year":"2009","unstructured":"Seeff, L.B. The history of the \u201cnatural history\u201d of hepatitis C (1968\u20132009). Liver Int. 29 Suppl. 1, 89\u201399 (2009).","journal-title":"Liver Int."},{"key":"BFnm3253_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1086\/595848","volume":"48","author":"V Soriano","year":"2009","unstructured":"Soriano, V., Peters, M.G. & Zeuzem, S. New therapies for hepatitis C virus infection. Clin. Infect. Dis. 48, 313\u2013320 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"BFnm3253_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/nrgastro.2011.49","volume":"8","author":"WP Hofmann","year":"2011","unstructured":"Hofmann, W.P. & Zeuzem, S. A new standard of care for the treatment of chronic HCV infection. Nat. Rev. Gastroenterol. Hepatol. 8, 257\u2013264 (2011).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"Suppl. 1","key":"BFnm3253_CR5","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","volume":"56","author":"C Sarrazin","year":"2012","unstructured":"Sarrazin, C., Hezode, C., Zeuzem, S. & Pawlotsky, J.M. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56 Suppl. 1, S88\u2013S100 (2012).","journal-title":"J. Hepatol."},{"key":"BFnm3253_CR6","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-\u03b1 and ribavirin therapy. Nat. Genet. 41, 1100\u20131104 (2009).","journal-title":"Nat. Genet."},{"key":"BFnm3253_CR7","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-\u03b1 and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105\u20131109 (2009).","journal-title":"Nat. Genet."},{"key":"BFnm3253_CR8","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas, D.L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798\u2013801 (2009).","journal-title":"Nature"},{"key":"BFnm3253_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399\u2013401 (2009).","journal-title":"Nature"},{"key":"BFnm3253_CR10","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","volume":"138","author":"A Rauch","year":"2010","unstructured":"Rauch, A. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138, 1338\u20131345, 1345.e1\u20137 (2010).","journal-title":"Gastroenterology"},{"key":"BFnm3253_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1055\/s-2005-864785","volume":"25","author":"P Andr\u00e9","year":"2005","unstructured":"Andr\u00e9, P., Perlemuter, G., Budkowska, A., Brechot, C. & Lotteau, V. Hepatitis C virus particles and lipoprotein metabolism. Semin. Liver Dis. 25, 93\u2013104 (2005).","journal-title":"Semin. Liver Dis."},{"key":"BFnm3253_CR12","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/nature04079","volume":"436","author":"DG Bowen","year":"2005","unstructured":"Bowen, D.G. & Walker, C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436, 946\u2013952 (2005).","journal-title":"Nature"},{"key":"BFnm3253_CR13","doi-asserted-by":"publisher","first-page":"15669","DOI":"10.1073\/pnas.202608199","volume":"99","author":"AI Su","year":"2002","unstructured":"Su, A.I. et al. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 99, 15669\u201315674 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3253_CR14","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nm.3251","volume":"19","author":"B Rehermann","year":"2013","unstructured":"Rehermann, B. Pathogenesis of chronic viral hepatitis: differential roles of T and natural killer cells Nat. Med. 19, 859\u2013868 (2013).","journal-title":"Nat. Med."},{"key":"BFnm3253_CR15","doi-asserted-by":"publisher","first-page":"e1000757","DOI":"10.1371\/journal.ppat.1000757","volume":"6","author":"MS Suthar","year":"2010","unstructured":"Suthar, M.S. et al. IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog. 6, e1000757 (2010).","journal-title":"PLoS Pathog."},{"key":"BFnm3253_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1574-6976.2011.00319.x","volume":"36","author":"R Thimme","year":"2012","unstructured":"Thimme, R., Binder, M. & Bartenschlager, R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol. Rev. 36, 663\u2013683 (2012).","journal-title":"FEMS Microbiol. Rev."},{"key":"BFnm3253_CR17","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/emboj\/16.2.406","volume":"16","author":"A Kumar","year":"1997","unstructured":"Kumar, A. et al. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-kappaB. EMBO J. 16, 406\u2013416 (1997).","journal-title":"EMBO J."},{"key":"BFnm3253_CR18","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1074\/jbc.M807888200","volume":"284","author":"CS McAllister","year":"2009","unstructured":"McAllister, C.S. & Samuel, C.E. The RNA-activated protein kinase enhances the induction of interferon-beta and apoptosis mediated by cytoplasmic RNA sensors. J. Biol. Chem. 284, 1644\u20131651 (2009).","journal-title":"J. Biol. Chem."},{"key":"BFnm3253_CR19","doi-asserted-by":"publisher","first-page":"6001","DOI":"10.1073\/pnas.0601523103","volume":"103","author":"YM Loo","year":"2006","unstructured":"Loo, Y.M. et al. Viral and therapeutic control of IFN-\u03b2 promoter stimulator 1 during hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 103, 6001\u20136006 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3253_CR20","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature07106","volume":"454","author":"T Saito","year":"2008","unstructured":"Saito, T., Owen, D.M., Jiang, F., Marcotrigiano, J. & Gale, M. Jr. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454, 523\u2013527 (2008).","journal-title":"Nature"},{"key":"BFnm3253_CR21","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1128\/JVI.02449-08","volume":"83","author":"D Uzri","year":"2009","unstructured":"Uzri, D. & Gehrke, L. Nucleotide sequences and modifications that determine RIG-I\/RNA binding and signaling activities. J. Virol. 83, 4174\u20134184 (2009).","journal-title":"J. Virol."},{"key":"BFnm3253_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1128\/JVI.01796-07","volume":"82","author":"S You","year":"2008","unstructured":"You, S. & Rice, C.M. 3\u2032 RNA elements in hepatitis C virus replication: kissing partners and long poly(U). J. Virol. 82, 184\u2013195 (2008).","journal-title":"J. Virol."},{"key":"BFnm3253_CR23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1073\/pnas.0606699104","volume":"104","author":"T Saito","year":"2007","unstructured":"Saito, T. et al. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc. Natl. Acad. Sci. USA 104, 582\u2013587 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3253_CR24","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.chom.2012.04.006","volume":"11","author":"HM Liu","year":"2012","unstructured":"Liu, H.M. et al. The mitochondrial targeting chaperone 14\u20133-3e regulates a RIG-I translocon that mediates membrane association and innate antiviral immunity. Cell Host Microbe 11, 528\u2013537 (2012).","journal-title":"Cell Host Microbe"},{"key":"BFnm3253_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature10537","volume":"479","author":"F Jiang","year":"2011","unstructured":"Jiang, F. et al. Structural basis of RNA recognition and activation by innate immune receptor RIG-I. Nature 479, 423\u2013427 (2011).","journal-title":"Nature"},{"key":"BFnm3253_CR26","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/nature05732","volume":"446","author":"MU Gack","year":"2007","unstructured":"Gack, M.U. et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I\u2013mediated antiviral activity. Nature 446, 916\u2013920 (2007).","journal-title":"Nature"},{"key":"BFnm3253_CR27","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.immuni.2011.05.003","volume":"34","author":"YM Loo","year":"2011","unstructured":"Loo, Y.M. & Gale, M. Jr. Immune signaling by RIG-I\u2013like receptors. Immunity 34, 680\u2013692 (2011).","journal-title":"Immunity"},{"key":"BFnm3253_CR28","doi-asserted-by":"publisher","first-page":"9824","DOI":"10.1128\/JVI.01125-09","volume":"83","author":"N Wang","year":"2009","unstructured":"Wang, N. et al. Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J. Virol. 83, 9824\u20139834 (2009).","journal-title":"J. Virol."},{"key":"BFnm3253_CR29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/hep.22306","volume":"48","author":"E Seki","year":"2008","unstructured":"Seki, E. & Brenner, D.A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48, 322\u2013335 (2008).","journal-title":"Hepatology"},{"key":"BFnm3253_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1600-065X.2008.00737.x","volume":"227","author":"O Takeuchi","year":"2009","unstructured":"Takeuchi, O. & Akira, S. Innate immunity to virus infection. Immunol. Rev. 227, 75\u201386 (2009).","journal-title":"Immunol. Rev."},{"key":"BFnm3253_CR31","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.4049\/jimmunol.176.8.4894","volume":"176","author":"B Salaun","year":"2006","unstructured":"Salaun, B., Coste, I., Rissoan, M.C., Lebecque, S.J. & Renno, T. TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol. 176, 4894\u20134901 (2006).","journal-title":"J. Immunol."},{"key":"BFnm3253_CR32","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/hep.24763","volume":"55","author":"K Li","year":"2012","unstructured":"Li, K. et al. Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology 55, 666\u2013675 (2012).","journal-title":"Hepatology"},{"key":"BFnm3253_CR33","doi-asserted-by":"publisher","first-page":"e1003345","DOI":"10.1371\/journal.ppat.1003345","volume":"9","author":"H Dansako","year":"2013","unstructured":"Dansako, H. et al. Class A scavenger receptor 1 (MSR1) restricts hepatitis C virus replication by mediating Toll-like receptor 3 recognition of viral RNAs produced in neighboring cells. PLoS Pathog. 9, e1003345 (2013).","journal-title":"PLoS Pathog."},{"key":"BFnm3253_CR34","doi-asserted-by":"publisher","first-page":"14046","DOI":"10.1073\/pnas.0907344106","volume":"106","author":"M Dreux","year":"2009","unstructured":"Dreux, M., Gastaminza, P., Wieland, S.F. & Chisari, F.V. The autophagy machinery is required to initiate hepatitis C virus replication. Proc. Natl. Acad. Sci. USA 106, 14046\u201314051 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3253_CR35","doi-asserted-by":"publisher","first-page":"e1002289","DOI":"10.1371\/journal.ppat.1002289","volume":"7","author":"N Arnaud","year":"2011","unstructured":"Arnaud, N. et al. Hepatitis C virus reveals a novel early control in acute immune response. PLoS Pathog. 7, e1002289 (2011).","journal-title":"PLoS Pathog."},{"key":"BFnm3253_CR36","doi-asserted-by":"publisher","first-page":"e10575","DOI":"10.1371\/journal.pone.0010575","volume":"5","author":"N Arnaud","year":"2010","unstructured":"Arnaud, N. et al. Hepatitis C virus controls interferon production through PKR activation. PLoS ONE 5, e10575 (2010).","journal-title":"PLoS ONE"},{"key":"BFnm3253_CR37","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.chom.2009.11.004","volume":"6","author":"U Garaigorta","year":"2009","unstructured":"Garaigorta, U. & Chisari, F.V. Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe 6, 513\u2013522 (2009).","journal-title":"Cell Host Microbe"},{"key":"BFnm3253_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1006\/viro.2002.1455","volume":"297","author":"G Koev","year":"2002","unstructured":"Koev, G., Duncan, R.F. & Lai, M.M. Hepatitis C virus IRES-dependent translation is insensitive to an eIF2\u03b1-independent mechanism of inhibition by interferon in hepatocyte cell lines. Virology 297, 195\u2013202 (2002).","journal-title":"Virology"},{"key":"BFnm3253_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.antiviral.2009.05.004","volume":"83","author":"T Shimoike","year":"2009","unstructured":"Shimoike, T., McKenna, S.A., Lindhout, D.A. & Puglisi, J.D. Translational insensitivity to potent activation of PKR by HCV IRES RNA. Antiviral Res. 83, 228\u2013237 (2009).","journal-title":"Antiviral Res."},{"key":"BFnm3253_CR40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature09907","volume":"472","author":"JW Schoggins","year":"2011","unstructured":"Schoggins, J.W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481\u2013485 (2011).","journal-title":"Nature"},{"key":"BFnm3253_CR41","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.coviro.2011.10.008","volume":"1","author":"JW Schoggins","year":"2011","unstructured":"Schoggins, J.W. & Rice, C.M. Interferon-stimulated genes and their antiviral effector functions. Curr. Opin. Virol. 1, 519\u2013525 (2011).","journal-title":"Curr. Opin. Virol."},{"key":"BFnm3253_CR42","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1089\/jir.2009.0063","volume":"29","author":"SM Horner","year":"2009","unstructured":"Horner, S.M. & Gale, M. Jr. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J. Interferon Cytokine Res. 29, 489\u2013498 (2009).","journal-title":"J. Interferon Cytokine Res."},{"key":"BFnm3253_CR43","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1002\/hep.25575","volume":"55","author":"L Liu","year":"2012","unstructured":"Liu, L., Fisher, B.E., Thomas, D.L., Cox, A.L. & Ray, S.C. Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology 55, 1684\u20131691 (2012).","journal-title":"Hepatology"},{"key":"BFnm3253_CR44","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2893.2011.01451.x","volume":"18","author":"K Morikawa","year":"2011","unstructured":"Morikawa, K. et al. Nonstructural protein 3\u20134A: the Swiss army knife of hepatitis C virus. J. Viral Hepat. 18, 305\u2013315 (2011).","journal-title":"J. Viral Hepat."},{"key":"BFnm3253_CR45","doi-asserted-by":"publisher","first-page":"14545","DOI":"10.1073\/pnas.0807298105","volume":"105","author":"V Brass","year":"2008","unstructured":"Brass, V. et al. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3\u20134A complex. Proc. Natl. Acad. Sci. USA 105, 14545\u201314550 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3253_CR46","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1128\/JVI.06727-11","volume":"86","author":"SM Horner","year":"2012","unstructured":"Horner, S.M., Park, H.S. & Gale, M. Jr. Control of innate immune signaling and membrane targeting by the hepatitis C virus NS3\/4A protease are governed by the NS3 helix \u03b10. J. Virol. 86, 3112\u20133120 (2012).","journal-title":"J. Virol."},{"key":"BFnm3253_CR47","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1126\/science.1082604","volume":"300","author":"E Foy","year":"2003","unstructured":"Foy, E. et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300, 1145\u20131148 (2003).","journal-title":"Science"},{"key":"BFnm3253_CR48","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1073\/pnas.0408707102","volume":"102","author":"E Foy","year":"2005","unstructured":"Foy, E. et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid\u2013inducible gene-I signaling. Proc. Natl. Acad. Sci. USA 102, 2986\u20132991 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3253_CR49","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nature04193","volume":"437","author":"E Meylan","year":"2005","unstructured":"Meylan, E. et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167\u20131172 (2005).","journal-title":"Nature"},{"key":"BFnm3253_CR50","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1128\/JVI.01659-08","volume":"83","author":"M Baril","year":"2009","unstructured":"Baril, M., Racine, M.E., Penin, F. & Lamarre, D. MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3\/4A protease. J. Virol. 83, 1299\u20131311 (2009).","journal-title":"J. Virol."},{"key":"BFnm3253_CR51","doi-asserted-by":"publisher","first-page":"17717","DOI":"10.1073\/pnas.0508531102","volume":"102","author":"XD Li","year":"2005","unstructured":"Li, X.D., Sun, L., Seth, R.B., Pineda, G. & Chen, Z.J. Hepatitis C virus protease NS3\/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. USA 102, 17717\u201317722 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3253_CR52","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1128\/JVI.02076-06","volume":"81","author":"Z Chen","year":"2007","unstructured":"Chen, Z. et al. GB virus B disrupts RIG-I signaling by NS3\/4A-mediated cleavage of the adaptor protein MAVS. J. Virol. 81, 964\u2013976 (2007).","journal-title":"J. Virol."},{"key":"BFnm3253_CR53","doi-asserted-by":"publisher","first-page":"7253","DOI":"10.1073\/pnas.0611506104","volume":"104","author":"Y Yang","year":"2007","unstructured":"Yang, Y. et al. Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc. Natl. Acad. Sci. USA 104, 7253\u20137258 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3253_CR54","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3389\/fmicb.2011.00240","volume":"2","author":"Y Iwasaki","year":"2011","unstructured":"Iwasaki, Y. et al. Long-term persistent GBV-B Infection and development of a chronic and progressive hepatitis C\u2013like disease in marmosets. Front. Microbiol. 2, 240 (2011).","journal-title":"Front. Microbiol."},{"key":"BFnm3253_CR55","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.1128\/JVI.02495-05","volume":"80","author":"R Lin","year":"2006","unstructured":"Lin, R. et al. Dissociation of a MAVS\/IPS-1\/VISA\/Cardif-IKKe molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3\u20134A proteolytic cleavage. J. Virol. 80, 6072\u20136083 (2006).","journal-title":"J. Virol."},{"key":"BFnm3253_CR56","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.cell.2005.08.012","volume":"122","author":"RB Seth","year":"2005","unstructured":"Seth, R.B., Sun, L., Ea, C.K. & Chen, Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kB and IRF 3. Cell 122, 669\u2013682 (2005).","journal-title":"Cell"},{"key":"BFnm3253_CR57","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.cell.2010.04.018","volume":"141","author":"E Dixit","year":"2010","unstructured":"Dixit, E. et al. Peroxisomes are signaling platforms for antiviral innate immunity. Cell 141, 668\u2013681 (2010).","journal-title":"Cell"},{"key":"BFnm3253_CR58","doi-asserted-by":"publisher","first-page":"14590","DOI":"10.1073\/pnas.1110133108","volume":"108","author":"SM Horner","year":"2011","unstructured":"Horner, S.M., Liu, H.M., Park, H.S., Briley, J. & Gale, M. Jr. Mitochondrial-associated endoplasmic reticulum membranes (MAM) form innate immune synapses and are targeted by hepatitis C virus. Proc. Natl. Acad. Sci. USA 108, 14590\u201314595 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3253_CR59","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.23426","volume":"51","author":"P Bellecave","year":"2010","unstructured":"Bellecave, P. et al. Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology 51, 1127\u20131136 (2010).","journal-title":"Hepatology"},{"key":"BFnm3253_CR60","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1073\/pnas.0408824102","volume":"102","author":"K Li","year":"2005","unstructured":"Li, K. et al. Immune evasion by hepatitis C virus NS3\/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. USA 102, 2992\u20132997 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3253_CR61","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.immuni.2011.03.027","volume":"34","author":"Z Zhang","year":"2011","unstructured":"Zhang, Z. et al. DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. Immunity 34, 866\u2013878 (2011).","journal-title":"Immunity"},{"key":"BFnm3253_CR62","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1006\/viro.1997.8493","volume":"230","author":"MJ Gale Jr","year":"1997","unstructured":"Gale, M.J. Jr . et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230, 217\u2013227 (1997).","journal-title":"Virology"},{"key":"BFnm3253_CR63","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1126\/science.285.5424.107","volume":"285","author":"DR Taylor","year":"1999","unstructured":"Taylor, D.R., Shi, S.T., Romano, P.R., Barber, G.N. & Lai, M.M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285, 107\u2013110 (1999).","journal-title":"Science"},{"key":"BFnm3253_CR64","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1348-0421.2001.tb01322.x","volume":"45","author":"T Noguchi","year":"2001","unstructured":"Noguchi, T. et al. Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells. Microbiol. Immunol. 45, 829\u2013840 (2001).","journal-title":"Microbiol. Immunol."},{"key":"BFnm3253_CR65","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1189\/jlb.69.6.912","volume":"69","author":"MJ de Veer","year":"2001","unstructured":"de Veer, M.J. et al. Functional classification of interferon-stimulated genes identified using microarrays. J. Leukoc. Biol. 69, 912\u2013920 (2001).","journal-title":"J. Leukoc. Biol."},{"key":"BFnm3253_CR66","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1056\/NEJMoa011232","volume":"345","author":"E Jaeckel","year":"2001","unstructured":"Jaeckel, E. et al. Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med. 345, 1452\u20131457 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnm3253_CR67","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1099\/vir.0.80401-0","volume":"85","author":"P Simmonds","year":"2004","unstructured":"Simmonds, P. Genetic diversity and evolution of hepatitis C virus\u201415 years on. J. Gen. Virol. 85, 3173\u20133188 (2004).","journal-title":"J. Gen. Virol."},{"key":"BFnm3253_CR68","doi-asserted-by":"publisher","first-page":"e6579","DOI":"10.1371\/journal.pone.0006579","volume":"4","author":"PS Pang","year":"2009","unstructured":"Pang, P.S., Planet, P.J. & Glenn, J.S. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS ONE 4, e6579 (2009).","journal-title":"PLoS ONE"},{"key":"BFnm3253_CR69","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.1073\/pnas.0707882105","volume":"105","author":"M Sarasin-Filipowicz","year":"2008","unstructured":"Sarasin-Filipowicz, M. et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. USA 105, 7034\u20137039 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3253_CR70","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1053\/j.gastro.2010.11.039","volume":"140","author":"MT Dill","year":"2011","unstructured":"Dill, M.T. et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140, 1021\u20131031 (2011).","journal-title":"Gastroenterology"},{"key":"BFnm3253_CR71","first-page":"1123\u20131133.e1","volume":"138","author":"L Chen","year":"2010","unstructured":"Chen, L. et al. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology 138, 1123\u20131133.e1\u20133 (2010).","journal-title":"Gastroenterology"},{"key":"BFnm3253_CR72","doi-asserted-by":"publisher","first-page":"8211","DOI":"10.1128\/JVI.00487-07","volume":"81","author":"MJ Donlin","year":"2007","unstructured":"Donlin, M.J. et al. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J. Virol. 81, 8211\u20138224 (2007).","journal-title":"J. Virol."},{"key":"BFnm3253_CR73","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1002\/hep.25908","volume":"56","author":"P Metz","year":"2012","unstructured":"Metz, P. et al. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology 56, 2082\u20132093 (2012).","journal-title":"Hepatology"},{"key":"BFnm3253_CR74","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1053\/j.gastro.2010.04.049","volume":"139","author":"M Honda","year":"2010","unstructured":"Honda, M. et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139, 499\u2013509 (2010).","journal-title":"Gastroenterology"},{"key":"BFnm3253_CR75","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1053\/j.gastro.2012.10.044","volume":"144","author":"DT Lau","year":"2013","unstructured":"Lau, D.T. et al. Innate immune tolerance and the role of Kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 144, 402\u2013413.e12 (2013).","journal-title":"Gastroenterology"},{"key":"BFnm3253_CR76","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/hep.23912","volume":"52","author":"TJ Urban","year":"2010","unstructured":"Urban, T.J. et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52, 1888\u20131896 (2010).","journal-title":"Hepatology"},{"key":"BFnm3253_CR77","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1053\/j.gastro.2010.07.058","volume":"139","author":"T Fukuhara","year":"2010","unstructured":"Fukuhara, T. et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 139, 1577\u20131585, 1585.e1\u20133 (2010).","journal-title":"Gastroenterology"},{"key":"BFnm3253_CR78","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jhep.2010.08.020","volume":"54","author":"B Langhans","year":"2011","unstructured":"Langhans, B. et al. Interferon-l serum levels in hepatitis C. J. Hepatol. 54, 859\u2013865 (2011).","journal-title":"J. Hepatol."},{"key":"BFnm3253_CR79","doi-asserted-by":"publisher","first-page":"e31016","DOI":"10.1371\/journal.pone.0031016","volume":"7","author":"M de Castellarnau","year":"2012","unstructured":"de Castellarnau, M. et al. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-\u03b1 and ribavirin therapy in HCV\/HIV-1 coinfected patients. PLoS ONE 7, e31016 (2012).","journal-title":"PLoS ONE"},{"key":"BFnm3253_CR80","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1002\/hep.24263","volume":"53","author":"J di Iulio","year":"2011","unstructured":"di Iulio, J. et al. Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology 53, 1446\u20131454 (2011).","journal-title":"Hepatology"},{"key":"BFnm3253_CR81","doi-asserted-by":"publisher","first-page":"e26620","DOI":"10.1371\/journal.pone.0026620","volume":"6","author":"M Sugiyama","year":"2011","unstructured":"Sugiyama, M., Tanaka, Y., Wakita, T., Nakanishi, M. & Mizokami, M. Genetic variation of the IL-28B promoter affecting gene expression. PLoS ONE 6, e26620 (2011).","journal-title":"PLoS ONE"},{"key":"BFnm3253_CR82","doi-asserted-by":"publisher","unstructured":"Raglow, Z., Thoma-Perry, C., Gilroy, R. & Wan, Y.J. IL28B genotype and the expression of ISGs in normal liver. Liver Int. published online, http:\/\/dx.doi.org\/10.1111\/liv.12148 (24 March 2013).","DOI":"10.1111\/liv.12148"},{"key":"BFnm3253_CR83","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/hep.25647","volume":"56","author":"S Naggie","year":"2012","unstructured":"Naggie, S. et al. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology 56, 444\u2013454 (2012).","journal-title":"Hepatology"},{"key":"BFnm3253_CR84","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/ng.2521","volume":"45","author":"L Prokunina-Olsson","year":"2013","unstructured":"Prokunina-Olsson, L. et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45, 164\u2013171 (2013).","journal-title":"Nat. Genet."},{"key":"BFnm3253_CR85","doi-asserted-by":"publisher","unstructured":"Bibert, S. et al. IL28B expression depends on a novel TT\/-G polymorphism which improves HCV clearance prediction. J. Exp. Med. published online, http:\/\/dx.doi.org\/10.1084\/jem.20130012 (27 May 2013).","DOI":"10.1084\/jem.20130012"},{"key":"BFnm3253_CR86","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1136\/gut.2010.222976","volume":"60","author":"C Kelly","year":"2011","unstructured":"Kelly, C., Klenerman, P. & Barnes, E. Interferon ls: the next cytokine storm. Gut 60, 1284\u20131293 (2011).","journal-title":"Gut"},{"key":"BFnm3253_CR87","doi-asserted-by":"publisher","first-page":"e1000017","DOI":"10.1371\/journal.ppat.1000017","volume":"4","author":"C Sommereyns","year":"2008","unstructured":"Sommereyns, C., Paul, S., Staeheli, P. & Michiels, T. IFN-lambda (IFN-l) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 4, e1000017 (2008).","journal-title":"PLoS Pathog."},{"key":"BFnm3253_CR88","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1053\/j.gastro.2006.09.052","volume":"131","author":"T Marcello","year":"2006","unstructured":"Marcello, T. et al. Interferons \u03b1 and l inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131, 1887\u20131898 (2006).","journal-title":"Gastroenterology"},{"key":"BFnm3253_CR89","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/hep.24189","volume":"53","author":"Z Makowska","year":"2011","unstructured":"Makowska, Z., Duong, F.H., Trincucci, G., Tough, D.F. & Heim, M.H. Interferon-beta and interferon-l signaling is not affected by interferon-induced refractoriness to interferon-\u03b1 in vivo. Hepatology 53, 1154\u20131163 (2011).","journal-title":"Hepatology"},{"key":"BFnm3253_CR90","doi-asserted-by":"publisher","first-page":"30079","DOI":"10.1074\/jbc.M804296200","volume":"283","author":"NE Pagliaccetti","year":"2008","unstructured":"Pagliaccetti, N.E. et al. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J. Biol. Chem. 283, 30079\u201330089 (2008).","journal-title":"J. Biol. Chem."},{"key":"BFnm3253_CR91","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1053\/j.gastro.2012.01.028","volume":"142","author":"I McGilvray","year":"2012","unstructured":"McGilvray, I. et al. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 142, 1122\u20131131.e1 (2012).","journal-title":"Gastroenterology"},{"key":"BFnm3253_CR92","doi-asserted-by":"publisher","first-page":"e1003330","DOI":"10.1371\/journal.ppat.1003330","volume":"9","author":"AA Negash","year":"2013","unstructured":"Negash, A.A. et al. IL-1\u03b2 production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog. 9, e1003330 (2013).","journal-title":"PLoS Pathog."},{"key":"BFnm3253_CR93","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/hep.24623","volume":"55","author":"Y Asahina","year":"2012","unstructured":"Asahina, Y. et al. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology 55, 20\u201329 (2012).","journal-title":"Hepatology"},{"key":"BFnm3253_CR94","doi-asserted-by":"publisher","first-page":"7431","DOI":"10.1073\/pnas.1002301107","volume":"107","author":"K Takahashi","year":"2010","unstructured":"Takahashi, K. et al. Plasmacytoid dendritic cells sense hepatitis C virus\u2013infected cells, produce interferon, and inhibit infection. Proc. Natl. Acad. Sci. USA 107, 7431\u20137436 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm3253_CR95","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/hep.22076","volume":"47","author":"DT Lau","year":"2008","unstructured":"Lau, D.T. et al. Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. Hepatology 47, 799\u2013809 (2008).","journal-title":"Hepatology"},{"key":"BFnm3253_CR96","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/hep.24580","volume":"54","author":"S Marukian","year":"2011","unstructured":"Marukian, S. et al. Hepatitis C virus induces interferon-l and interferon-stimulated genes in primary liver cultures. Hepatology 54, 1913\u20131923 (2011).","journal-title":"Hepatology"},{"key":"BFnm3253_CR97","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/j.gastro.2011.12.055","volume":"142","author":"E Thomas","year":"2012","unstructured":"Thomas, E. et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 142, 978\u2013988 (2012).","journal-title":"Gastroenterology"},{"key":"BFnm3253_CR98","doi-asserted-by":"publisher","first-page":"e1003316","DOI":"10.1371\/journal.ppat.1003316","volume":"9","author":"AE Stone","year":"2013","unstructured":"Stone, A.E. et al. Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of l-interferons by human plasmacytoid dendritic cells. PLoS Pathog. 9, e1003316 (2013).","journal-title":"PLoS Pathog."},{"key":"BFnm3253_CR99","doi-asserted-by":"publisher","unstructured":"Nishitsuji, H. et al. HCV infection induces inflammatory cytokines and chemokines mediated by the cross-talk between hepatocytes and stellate cells. J. Virol. published online, http:\/\/dx.doi.org\/10.1128\/JVI.00974-13 (15 May 2013).","DOI":"10.1128\/JVI.00974-13"},{"key":"BFnm3253_CR100","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jhep.2012.10.019","volume":"58","author":"CM Lange","year":"2013","unstructured":"Lange, C.M. & Zeuzem, S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J. Hepatol. 58, 583\u2013592 (2013).","journal-title":"J. Hepatol."},{"key":"BFnm3253_CR101","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1128\/JVI.79.5.2689-2699.2005","volume":"79","author":"R Sumpter Jr","year":"2005","unstructured":"Sumpter, R. Jr . et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 79, 2689\u20132699 (2005).","journal-title":"J. Virol."},{"key":"BFnm3253_CR102","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1128\/JVI.02113-07","volume":"82","author":"D Jiang","year":"2008","unstructured":"Jiang, D. et al. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J. Virol. 82, 1665\u20131678 (2008).","journal-title":"J. Virol."},{"key":"BFnm3253_CR103","doi-asserted-by":"publisher","first-page":"9713","DOI":"10.1128\/JVI.78.18.9713-9720.2004","volume":"78","author":"N Kanazawa","year":"2004","unstructured":"Kanazawa, N. et al. Regulation of hepatitis C virus replication by interferon regulatory factor 1. J. Virol. 78, 9713\u20139720 (2004).","journal-title":"J. Virol."},{"key":"BFnm3253_CR104","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.1128\/MCB.18.9.5208","volume":"18","author":"M Gale Jr","year":"1998","unstructured":"Gale, M. Jr . et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol. Cell. Biol. 18, 5208\u20135218 (1998).","journal-title":"Mol. Cell. Biol."},{"key":"BFnm3253_CR105","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/j.1365-2893.2006.00732.x","volume":"13","author":"Y Itsui","year":"2006","unstructured":"Itsui, Y. et al. Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication. J. Viral Hepat. 13, 690\u2013700 (2006).","journal-title":"J. Viral Hepat."},{"key":"BFnm3253_CR106","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/ni.2048","volume":"12","author":"A Pichlmair","year":"2011","unstructured":"Pichlmair, A. et al. IFIT1 is an antiviral protein that recognizes 5\u2032-triphosphate RNA. Nat. Immunol. 12, 624\u2013630 (2011).","journal-title":"Nat. Immunol."},{"key":"BFnm3253_CR107","doi-asserted-by":"publisher","first-page":"12881","DOI":"10.1128\/JVI.05633-11","volume":"85","author":"A Raychoudhuri","year":"2011","unstructured":"Raychoudhuri, A. et al. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J. Virol. 85, 12881\u201312889 (2011).","journal-title":"J. Virol."},{"key":"BFnm3253_CR108","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1128\/JVI.77.7.3898-3912.2003","volume":"77","author":"C Wang","year":"2003","unstructured":"Wang, C. et al. \u03b1-interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J. Virol. 77, 3898\u20133912 (2003).","journal-title":"J. Virol."},{"key":"BFnm3253_CR109","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.4049\/jimmunol.1100963","volume":"187","author":"XY Liu","year":"2011","unstructured":"Liu, X.Y., Chen, W., Wei, B., Shan, Y.F. & Wang, C. IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging MAVS and TBK1. J. Immunol. 187, 2559\u20132568 (2011).","journal-title":"J. Immunol."},{"key":"BFnm3253_CR110","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/hep.26066","volume":"57","author":"C Wilkins","year":"2013","unstructured":"Wilkins, C. et al. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 57, 461\u2013469 (2013).","journal-title":"Hepatology"},{"key":"BFnm3253_CR111","doi-asserted-by":"publisher","first-page":"e1001258","DOI":"10.1371\/journal.ppat.1001258","volume":"7","author":"IC Huang","year":"2011","unstructured":"Huang, I.C. et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 7, e1001258 (2011).","journal-title":"PLoS Pathog."},{"key":"BFnm3253_CR112","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1111\/j.1365-2893.2011.01452.x","volume":"18","author":"L Yao","year":"2011","unstructured":"Yao, L. et al. Identification of the IFITM3 gene as an inhibitor of hepatitis C viral translation in a stable STAT1 cell line. J. Viral Hepat. 18, e523\u2013e529 (2011).","journal-title":"J. Viral Hepat."},{"key":"BFnm3253_CR113","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.bbrc.2010.01.034","volume":"392","author":"M Ishibashi","year":"2010","unstructured":"Ishibashi, M., Wakita, T. & Esumi, M. 2\u2032,5\u2032-Oligoadenylate synthetase-like gene highly induced by hepatitis C virus infection in human liver is inhibitory to viral replication in vitro. Biochem. Biophys. Res. Commun. 392, 397\u2013402 (2010).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnm3253_CR114","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1017\/S1355838202020617","volume":"8","author":"JQ Han","year":"2002","unstructured":"Han, J.Q. & Barton, D.J. Activation and evasion of the antiviral 2\u2032-5\u2032 oligoadenylate synthetase\/ribonuclease L pathway by hepatitis C virus mRNA. RNA 8, 512\u2013525 (2002).","journal-title":"RNA"},{"key":"BFnm3253_CR115","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1002\/hep.24542","volume":"54","author":"KJ Helbig","year":"2011","unstructured":"Helbig, K.J. et al. The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A. Hepatology 54, 1506\u20131517 (2011).","journal-title":"Hepatology"},{"key":"BFnm3253_CR116","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/hep.20844","volume":"42","author":"KJ Helbig","year":"2005","unstructured":"Helbig, K.J., Lau, D.T., Semendric, L., Harley, H.A. & Beard, M.R. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 42, 702\u2013710 (2005).","journal-title":"Hepatology"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm.3253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.3253","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.3253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T19:43:49Z","timestamp":1688327029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm.3253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":116,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["BFnm3253"],"URL":"https:\/\/doi.org\/10.1038\/nm.3253","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}